Form 4: Iradimed Corp Insider Sells Shares Under 10b5-1 Plan

Roger E. Susi, CEO and Director of Iradimed Corp, reported the sale of common stock totaling 5,304 shares through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, who holds positions as CEO, President, Chairman, Director, and is a 10% owner of Iradimed Corporation, has reported transactions involving the sale of common stock.
• These sales occurred on April 20, 2026, and April 21, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on November 5, 2025, which is designed to satisfy affirmative defense conditions for insider trading.
• A total of 5,304 shares were sold across multiple transactions.
• The weighted average sale prices ranged from $89.18 to $94.14 per share.
• Following these transactions, Roger E. Susi's beneficial ownership of Iradimed Corp common stock is detailed, with some shares held indirectly through trusts and a revocable trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to insider selling, even though it was executed under a pre-planned Rule 10b5-1 trading plan.

Negatives

• Insider selling activity, while conducted under a pre-arranged plan, can sometimes be perceived negatively by the market.
• The total value of shares sold by Roger E. Susi amounts to approximately $470,000 based on the reported weighted average prices.

Risks

• The Rule 10b5-1 plan is designed to mitigate insider trading concerns, but the execution of sales by a key executive could still be interpreted by the market as a lack of confidence in future stock performance.
• While not explicitly stated as a risk in this filing, significant insider selling can sometimes precede negative company news or indicate that insiders believe the stock is fully valued.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It is a report of past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a CEO and significant shareholder like Roger E. Susi is a common practice to diversify holdings or manage personal finances while adhering to insider trading regulations. The specific timing and volume of sales under such plans can be closely watched by investors.

Stakeholder Impact

• Shareholders: May perceive insider selling as a negative signal, potentially impacting stock price, despite the Rule 10b5-1 plan.
• Management: Demonstrates adherence to regulatory requirements for insider trading through the use of a pre-arranged plan.
• Employees: May observe insider selling, which could influence their sentiment towards the company's stock performance.

Next Steps

• Continued monitoring of insider transactions for any further sales or purchases.
• Analysis of Iradimed Corporation's future financial performance and strategic announcements to contextualize the insider selling.

Key Dates

Recommendation

The filing reports insider stock sales under a Rule 10b5-1 plan, which is a standard practice. While insider selling can be a negative signal, the pre-planned nature mitigates concerns about immediate non-public information. Without further financial or strategic information from the company, a 'hold' recommendation is prudent, suggesting investors await more substantial company updates before making significant investment decisions.

Keywords

Iradimed Corp, IRMD, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, Roger E. Susi, CEO, Director